MedTrace Logo

Combination Chemotherapy in Treating Patients Who Have Extensive-Stage Small Cell Lung Cancer

NCT00003696 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective for extensive-stage small cell lung cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients with extensive-stage small cell lung cancer.

Conditions

Interventions

DRUG

carboplatin

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

paclitaxel

Sponsors & Collaborators

  • Commissie Voor Klinisch Toegepast Onderzoek

    lead OTHER

Principal Investigators

  • Egbert F. Smit, MD · Free University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003696 on ClinicalTrials.gov